MedTrace Logo

Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)

NCT00704769 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 591

Last updated 2022-02-09

Study results available
· View outcomes & findings →

Summary

Evaluate the safety and general clinical response of desloratadine syrup in the relief of symptoms associated with perennial allergic rhinitis in Indonesian pediatric patients.

Conditions

  • Rhinitis

Interventions

DRUG

Desloratadine (assigned by investigator as part of normal practice)

Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Eligibility

Min Age
2 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704769 on ClinicalTrials.gov